Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS) (EpidALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03366506
Recruitment Status : Recruiting
First Posted : December 8, 2017
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Hadassah Medical Organization

Brief Summary:

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:-

  1. Differences between ethnic subgroups
  2. Differences between immigrant and native-born populations
  3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

Condition or disease Intervention/treatment
ALS Other: Observation

Detailed Description:

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:-

  1. Differences between ethnic subgroups
  2. Differences between immigrant and native-born populations
  3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

The clinical features will include pattern of onset, details of full clinical exam ( including ALSFRS-R score, power, reflexes, and other signs of upper or lower-motor neuron dysfunction.

Correlations between different clinical parameters themselves will be made, as well as correlation between clinical parameters and other epidemiological factors.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)
Actual Study Start Date : March 9, 2009
Estimated Primary Completion Date : March 2049


Group/Cohort Intervention/treatment
ALS patients

ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).

Observation

Other: Observation



Primary Outcome Measures :
  1. Progression rate [ Time Frame: up to 10 years ]
    Progression of ALSFRS-R score over time


Secondary Outcome Measures :
  1. Appearance of clinical features of UMN or LMN dysfunction [ Time Frame: 10 years ]
    Appearance of clinical features of UMN or LMN dysfunction over time



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Population referred to ALS clinic with suspected, possible, probable ,definite ALS
Criteria

Inclusion Criteria:

- Suspected, possible, probable ,definite ALS

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03366506


Contacts
Layout table for location contacts
Contact: Marc Gotkine, MBBS +972507874692 marc@gotkine.com

Locations
Layout table for location information
Israel
Hadassah Medical Organisation Recruiting
Jerusalem, Israel, 91120
Contact: Marc Gotkine, MBBS    +972507874692    marc@gotkine.com   
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Layout table for investigator information
Principal Investigator: Marc Gotkine, MBBS hadassah medical organisation

Additional Information:

Layout table for additonal information
Responsible Party: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT03366506     History of Changes
Other Study ID Numbers: 0633-08-HMO-CTIL
First Posted: December 8, 2017    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Via specific collaboration agreements.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases